At a glance
ClinicalIndex Comparison RecordN/ACompleted· 566 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 3-year Post-marketing Observational Study Following up Patients With Moderate to Severe RA Treated With Humira in Greece
In Brief
An observational study for Rheumatoid Arthritis. Completed, enrolled 566 participants across 60 sites.
Detailed Summary
The objectives of the study are to observe and assess the long-term use, safety and efficacy of Humira (adalimumab), as prescribed by the rheumatologist in a normal clinical setting and in accordance with the terms of the European marketing authorization and to observe compliance of patients with the prescribed treatment.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesGreece
Collaborators--
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
First PostedMar 2010
Primary CompletionJul 2012
TodayJul 2026
First PostedMar 12, 2010
Enrollment StartMay 1, 2006
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 16.3 years ago